Inside the EladON Trial: One Patient's Experience After Islet Transplant and Teplizumab

The EladON trial is testing an approach that combines two separate treatments: islet cell transplantation and Teplizumab, an immunotherapy drug. One participant—identified as Patient Nine in the trial—recently shared her experience of what life has looked like six months after undergoing this combined procedure.

Islet cell transplants involve implanting insulin-producing cells from a donor pancreas. Teplizumab is a monoclonal antibody designed to help preserve the body's own insulin-producing capacity. Researchers are investigating whether using these two approaches together might extend or enhance the benefits of transplantation alone.

Patient Nine reports a dramatic shift in her daily life. Three months after her islet transplant, and 42 days after her last insulin injection, she was told to remove her continuous glucose monitor and "go live her life." For someone who had been managing Type 1 diabetes with constant monitoring and insulin dosing, this represented a fundamental change in how she experiences her health.

She describes the absence of CGM alarms, data checks before meals or workouts, and the ability to make spontaneous choices without worrying about blood sugar crashes. These shifts touch on both the practical and psychological aspects of living with Type 1 diabetes—moving beyond the mechanics of disease management to reclaim everyday freedom.

This patient's experience is one data point in an ongoing clinical trial. Individual outcomes in research settings do not represent what will happen for all patients or predict broader results. Islet cell transplantation itself carries risks, including the need for lifelong immunosuppression, and outcomes vary based on many factors including the quality of donor cells and individual biology.

The combination of islet transplantation with Teplizumab is being studied specifically because researchers believe the immunotherapy may help protect transplanted cells and improve long-term function. Early reports like this one provide hope and direction for future research, but they are not guarantees of similar outcomes for others.

Stories from clinical trial participants offer a window into what new treatments might make possible. Patient Nine's report—no insulin, no CGM, no diabetes management overhead—describes a profound change in quality of life. At the same time, the full picture of islet transplantation includes ongoing medical care, immunosuppression, and monitoring to ensure the transplant continues to function.

As the EladON trial continues, researchers will track not only whether participants can stop insulin, but how long transplanted cells remain functional, what side effects emerge over time, and which patients are best suited for this approach. One patient's six-month experience is encouraging—and is also just the beginning of understanding what this combination strategy offers the broader Type 1 diabetes community.

Origin: YouTube / Diabetech (Video report). Evidence: Video report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.